Cosmo Pharmaceuticals CMOPF Stock
Cosmo Pharmaceuticals Price Chart
Cosmo Pharmaceuticals CMOPF Financial and Trading Overview
Cosmo Pharmaceuticals stock price | 62.8 USD |
Previous Close | 50.3 USD |
Open | 50.3 USD |
Bid | 0 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 50.3 - 50.3 USD |
52 Week Range | 47.5 - 68.9 USD |
Volume | 30 USD |
Avg. Volume | 24 USD |
Market Cap | 861.18M USD |
Beta (5Y Monthly) | 1.044444 |
PE Ratio (TTM) | 44.513275 |
EPS (TTM) | 4.7 USD |
Forward Dividend & Yield | 1.13 (2.25%) |
Ex-Dividend Date | May 31, 2023 |
1y Target Est | N/A |
CMOPF Valuation Measures
Enterprise Value | 757.39M USD |
Trailing P/E | 44.513275 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 8.435544 |
Price/Book (mrq) | 1.7899718 |
Enterprise Value/Revenue | 7.419 |
Enterprise Value/EBITDA | 18.397 |
Trading Information
Cosmo Pharmaceuticals Stock Price History
Beta (5Y Monthly) | 1.044444 |
52-Week Change | 5.89% |
S&P500 52-Week Change | 20.43% |
52 Week High | 68.9 USD |
52 Week Low | 47.5 USD |
50-Day Moving Average | 59.76 USD |
200-Day Moving Average | 60.58 USD |
CMOPF Share Statistics
Avg. Volume (3 month) | 24 USD |
Avg. Daily Volume (10-Days) | 3 USD |
Shares Outstanding | 16.26M |
Float | 8.69M |
Short Ratio | N/A |
% Held by Insiders | 47.28% |
% Held by Institutions | 11.66% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 1.05 |
Trailing Annual Dividend Yield | 2.08% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.90559995 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 16.87% |
Operating Margin (ttm) | 27.48% |
Gross Margin | 60.34% |
EBITDA Margin | 40.32% |
Management Effectiveness
Return on Assets (ttm) | 2.24% |
Return on Equity (ttm) | 3.58% |
Income Statement
Revenue (ttm) | 102.09M USD |
Revenue Per Share (ttm) | 6.22 USD |
Quarterly Revenue Growth (yoy) | 65.29% |
Gross Profit (ttm) | N/A |
EBITDA | 41.17M USD |
Net Income Avi to Common (ttm) | 17.23M USD |
Diluted EPS (ttm) | 1.13 |
Quarterly Earnings Growth (yoy) | -65.90% |
Balance Sheet
Total Cash (mrq) | 240.95M USD |
Total Cash Per Share (mrq) | 14.82 USD |
Total Debt (mrq) | 173.6M USD |
Total Debt/Equity (mrq) | 37.43 USD |
Current Ratio (mrq) | 1.57 |
Book Value Per Share (mrq) | 28.101 |
Cash Flow Statement
Operating Cash Flow (ttm) | 33.23M USD |
Levered Free Cash Flow (ttm) | 11.7M USD |
Profile of Cosmo Pharmaceuticals
Country | United States |
State | N/A |
City | Dublin |
Address | Riverside II |
ZIP | 2 |
Phone | 353 1 817 0370 |
Website | https://www.cosmopharma.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 295 |
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, Parmascience Inc., RedHill Biopharma Ltd., Dr. Falk Pharma, Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Q&A For Cosmo Pharmaceuticals Stock
What is a current CMOPF stock price?
Cosmo Pharmaceuticals CMOPF stock price today per share is 62.8 USD.
How to purchase Cosmo Pharmaceuticals stock?
You can buy CMOPF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cosmo Pharmaceuticals?
The stock symbol or ticker of Cosmo Pharmaceuticals is CMOPF.
Which industry does the Cosmo Pharmaceuticals company belong to?
The Cosmo Pharmaceuticals industry is Drug Manufacturers-General.
How many shares does Cosmo Pharmaceuticals have in circulation?
The max supply of Cosmo Pharmaceuticals shares is 16.02M.
What is Cosmo Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Cosmo Pharmaceuticals PE Ratio is 13.36170300 now.
What was Cosmo Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Cosmo Pharmaceuticals EPS is 4.7 USD over the trailing 12 months.
Which sector does the Cosmo Pharmaceuticals company belong to?
The Cosmo Pharmaceuticals sector is Healthcare.